INVEST IN OUR FUTURE
INVEST IN OUR FUTURE
INVEST IN OUR FUTURE

A targeted investment strategy

Xerys is a portfolio management company specialising in private equity with an approach that makes the entrepreneur’s vision central to its investment philosophy. It aims to support the managers of Xerys Funds portfolio companies at all stages of their growth, from venture capital to maturity.

JACQUES SIMONNET

Chairman of the supervisory board and founder

OLIVIER OSSIPOFF

Chairman

OUR PHILOSOPHY

The Xerys approach

« The creation of Xerys aims to meet the need to reconcile two major issues for business growth. On the one hand, entrepreneurs who wish to successfully carry out their growth ambitions need tailored, financial guidance but also strategic and operational support. On the other hand, investors are looking for transparency and control of their investments.…

AN ORIGINAL APPROACH TO A CAPITAL INVESTOR

100%

INDEPENDENT

10-80M€

INVESTMENT
TICKET

6

COMPANIES
IN PORTFOLIO

2014

Approval of the Authority
Financial Markets

Strong expertise

The governance of Xerys Invest is structured around a supervisory board and a directory with complementary experiences

Strong involvement

The management team and the experts are involved in the monitoring of the participations

Convergent interests

The management team is systematically interested in the performance of investments

Xerys therefore immediately establishes a constructive and proactive proximity relationship with the managers of its investments to assist and advise them in their strategic decision-making, arbitration and value creation.
With this original approach, Xerys establishes a relationship of trust with managers and investors, fostering a creation of shared value over the medium term.

3 SECTORS OF INVESTMENT

Santé

Sustainable
development

Connected
Technologies

NEWS

SKYTECH continues its expansion in Italy and announces the signature of a distribution partnership with Polytrade

Le Val d'Hazey, December 1st, 2022 - As part of its development in Italy, SKYTECH, the French greentech specializing in ...
Lire La Suite…

ADVANCED BIODESIGN ANNOUNCES THE START OF THE FIRST-IN-HUMAN CLINICAL TRIAL “ODYSSEY” TARGETING ACUTE MYELOID LEUKAEMIA

After receiving an approval from the National Agency for Medicinal Safety and Health Products (ANSM), Advanced BioDesign announces today the ...
Lire La Suite…